Latest Administration News

LCL Resources reports promising trenching results at its Ubei project in Papua New Guinea, including a standout grab sample with nearly 8g/t gold, while advancing exploration and strategic options in Colombia.

Avecho Biotechnology advances its pivotal Phase III CBD insomnia trial with 160 patients dosed and secures $2.5 million to accelerate manufacturing and regulatory efforts ahead of a 2026 interim analysis.

Acrux Limited reports robust revenue growth in Q1 FY26, driven by strong profit share income from recently launched topical pharmaceuticals and a significant R&D tax rebate repayment.

European Metals Holdings has advanced its Cinovec Lithium Project with a new preliminary mining permit and secured funding to complete its Definitive Feasibility Study, reinforcing its position in Europe's critical raw materials landscape.

EVE Health Group has taken significant strides in commercialising its women’s and men’s health products Dyspro™ and Libbo™, securing regulatory clearances, first patient prescriptions, and raising $1.1 million to support market expansion.

Bowen Coking Coal maintained steady production and sales in Q3 2025 while slashing costs by a third through a new mining model, despite ongoing administration and receivership. The company generated positive operating cash flow and advanced key development projects.

Bowen Coking Coal Ltd has released its updated 2025 Coal Resources and Reserves statement, reflecting mining depletion and joint venture ownership changes amid ongoing administration. The report details nuanced shifts across key Queensland projects, underscoring operational challenges and asset continuity.

Bowen Coking Coal Ltd has released its mid-2025 update on coal resources and reserves across key Queensland projects, confirming 11 million tonnes of run-of-mine coal reserves at Ellensfield South and Plumtree North. The report also highlights a significant resource increase at Hillalong South and a steady reserve position at Broadmeadow East amid ongoing administration.

Simble Solutions reports new multi-year contracts in the UK and Australia, boosting revenue prospects, but faces a cash runway of less than one quarter and is exploring funding options.

Imugene Limited reports an 81% overall response rate in its azer-cel CAR T-cell therapy trial for difficult lymphomas, alongside a $25 million capital raise that extends its cash runway to mid-2027.

ADX Energy reports a 17% production dip in Q3 2025 due to well downtime but boosts sales revenue by 23%, while advancing drilling plans and acquiring key infrastructure.

Uscom Limited reported a 27% drop in cash reserves for Q1 2025, driven by declining revenue and rising costs, while preparing to sell its main business unit to stabilize finances.